Is AnaptysBio a Buy?
A promising pipeline, collaborations with deep-pocketed partners, and adequate financing are some of the things investors look for in clinical-stage biopharma companies. AnaptysBio (NASDAQ: ANAB) offers most of those things, but has recently discovered that "promising pipeline" is a subjective term.
On the one hand, the company has advanced five unique drug candidates across immunology and oncology indications into clinical trials. It has some wholly owned assets and some partnered with Tesaro -- now part of GlaxoSmithKline (NYSE: GSK) -- and Celgene. On the other hand, investors haven't been impressed with clinical results announced to date, including the latest batch three weeks ago.
But maybe the pharmaceutical stock's 52% year-to-date collapse is a bit of an overreaction. If that's the case, then is AnaptysBio a buy?
Source Fool.com
